AR034312A1 - Composicion de vacuna que comprende al menos un antigeno del virus de la inmunodeficiencia humana (vih), kit de vacunacion que la comprende, uso de un antigeno de vph y vhs para la preparacion de la composicion de vacuna y procedimiento para la preparacion de dicha vacuna - Google Patents

Composicion de vacuna que comprende al menos un antigeno del virus de la inmunodeficiencia humana (vih), kit de vacunacion que la comprende, uso de un antigeno de vph y vhs para la preparacion de la composicion de vacuna y procedimiento para la preparacion de dicha vacuna

Info

Publication number
AR034312A1
AR034312A1 ARP020101499A ARP020101499A AR034312A1 AR 034312 A1 AR034312 A1 AR 034312A1 AR P020101499 A ARP020101499 A AR P020101499A AR P020101499 A ARP020101499 A AR P020101499A AR 034312 A1 AR034312 A1 AR 034312A1
Authority
AR
Argentina
Prior art keywords
antigen
vaccine composition
preparation
hpv
hiv
Prior art date
Application number
ARP020101499A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of AR034312A1 publication Critical patent/AR034312A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición de vacuna que comprende: (a) al menos un antígeno del virus de la inmunodeficiencia humana (VIH); y uno o los dos siguientes: (b) al menos un antígeno del virus del herpes simplex (VHS) y (c) al menos un antígeno del virus de papiloma humano (VPH). El antígeno de VIH se puede seleccionar entre el grupo compuesto por gp160, gp120, nef, tat, un aproteína de fusión nef-tat ó tat-nef, gag, pol o derivados inmunológicamente activos de los mismos; el antígeno de VPH se puede seleccionar entre el grupo compuesto por L1, L2, E6 y E7 o combinaciones de los mismos, opcionalmente en forma de una proteína de fusión o un truncado; y el antígeno de VHS puede ser gD de VHS-2 o un truncado del mismo. Un kit de vacunación que comprende dicha composición de vacuna. Uso de un antígeno de VPH y de VHS para la preparación de una composición de vacuna para la prevención o tratamiento de la infección o enfermedad por VIH o VHS. Un procedimiento para la preparación de la composición de vacuna que comprende combinar al menos un antígeno del virus de inmunodeficiencia humana (VIH) con uno o los dos siguientes: i) al menos un antígeno del virus del herpes simplex (VHS); y ii) al menos un antígeno del virus de papiloma humano (VPH).
ARP020101499A 2001-04-27 2002-04-25 Composicion de vacuna que comprende al menos un antigeno del virus de la inmunodeficiencia humana (vih), kit de vacunacion que la comprende, uso de un antigeno de vph y vhs para la preparacion de la composicion de vacuna y procedimiento para la preparacion de dicha vacuna AR034312A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0110431A GB0110431D0 (en) 2001-04-27 2001-04-27 Novel compounds

Publications (1)

Publication Number Publication Date
AR034312A1 true AR034312A1 (es) 2004-02-18

Family

ID=9913641

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101499A AR034312A1 (es) 2001-04-27 2002-04-25 Composicion de vacuna que comprende al menos un antigeno del virus de la inmunodeficiencia humana (vih), kit de vacunacion que la comprende, uso de un antigeno de vph y vhs para la preparacion de la composicion de vacuna y procedimiento para la preparacion de dicha vacuna

Country Status (20)

Country Link
US (1) US20040131638A1 (es)
EP (1) EP1381390A2 (es)
JP (1) JP2004531540A (es)
KR (1) KR20040030599A (es)
CN (1) CN1522153A (es)
AR (1) AR034312A1 (es)
AU (1) AU2002310802B2 (es)
BR (1) BR0209161A (es)
CA (1) CA2445310A1 (es)
CZ (1) CZ20032942A3 (es)
GB (1) GB0110431D0 (es)
HU (1) HUP0303942A3 (es)
IL (1) IL158428A0 (es)
MX (1) MXPA03009698A (es)
MY (1) MY134041A (es)
NO (1) NO20034695L (es)
NZ (1) NZ529039A (es)
PL (1) PL367134A1 (es)
WO (1) WO2002087614A2 (es)
ZA (1) ZA200308188B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0405480D0 (en) * 2004-03-11 2004-04-21 Istituto Superiore Di Sanito Novel tat complexes,and vaccines comprising them
PE20060434A1 (es) * 2004-06-16 2006-06-08 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph
GB0413510D0 (en) * 2004-06-16 2004-07-21 Glaxosmithkline Biolog Sa Vaccine
WO2008082719A2 (en) * 2006-08-30 2008-07-10 University Of Rochester Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
JP5639361B2 (ja) 2006-09-08 2014-12-10 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｈｓｖ−１及びｈｓｖ−２ワクチン並びにその使用方法
WO2008085486A1 (en) 2006-12-28 2008-07-17 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US8057804B2 (en) 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US10478490B2 (en) 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
CN102099053A (zh) * 2008-05-26 2011-06-15 卡迪拉保健有限公司 麻疹-人乳头瘤组合疫苗
JP5568017B2 (ja) * 2008-12-25 2014-08-06 一般財団法人化学及血清療法研究所 組換え鶏伝染性コリーザワクチン及びその製造方法
AU2012298125B2 (en) * 2011-08-19 2015-09-24 Immortal Spirit Limited Antibody and antibody-containing composition
CN107001430A (zh) * 2014-10-24 2017-08-01 哈普威克斯有限责任公司 癌症和皮肤病变治疗
JP2019506435A (ja) * 2016-02-27 2019-03-07 エイチピーブイヴァックス, リミテッド ライアビリティー カンパニー.Hpvvax, Llc. ワクチンを使用して癌または皮膚病変を治療するための方法および組成物
AU2017389221B2 (en) * 2016-12-26 2020-10-08 Access To Advanced Health Institute Herpes zoster vaccine composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
DE60043708D1 (de) * 1999-10-13 2010-03-04 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen

Also Published As

Publication number Publication date
IL158428A0 (en) 2004-05-12
JP2004531540A (ja) 2004-10-14
NO20034695L (no) 2003-12-03
MXPA03009698A (es) 2004-01-29
KR20040030599A (ko) 2004-04-09
BR0209161A (pt) 2004-08-03
US20040131638A1 (en) 2004-07-08
MY134041A (en) 2007-11-30
CZ20032942A3 (cs) 2004-12-15
GB0110431D0 (en) 2001-06-20
CA2445310A1 (en) 2002-11-07
HUP0303942A2 (hu) 2004-03-01
PL367134A1 (en) 2005-02-21
EP1381390A2 (en) 2004-01-21
NZ529039A (en) 2005-02-25
HUP0303942A3 (en) 2005-11-28
WO2002087614A3 (en) 2003-04-24
AU2002310802B2 (en) 2005-03-24
NO20034695D0 (no) 2003-10-20
WO2002087614A2 (en) 2002-11-07
CN1522153A (zh) 2004-08-18
ZA200308188B (en) 2005-01-21

Similar Documents

Publication Publication Date Title
AR034312A1 (es) Composicion de vacuna que comprende al menos un antigeno del virus de la inmunodeficiencia humana (vih), kit de vacunacion que la comprende, uso de un antigeno de vph y vhs para la preparacion de la composicion de vacuna y procedimiento para la preparacion de dicha vacuna
Goepfert et al. Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles
Krowka et al. Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro.
Gilbert et al. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials
Epstein et al. Head and neck malignancies associated with HIV infection
EP1766096A4 (en) SIV AND HIV VACCINATION WITH RHCMV AND HCMV BASED IMPFECTORS
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
DE69632256D1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
ES2166779T3 (es) Complejos inmunogenicos del hiv.
CO5280045A1 (es) Nueva composicion
SG155206A1 (en) Vaccine for prevention and treatment of hiv-infection
PE43298A1 (es) Genes sinteticos de vih
BR9814606A (pt) Formulação de vacina e métodos de tratamento de um indivìduo infectado com um vìrus hpv e de prevenção de infecção por papiloma vìrus
NO921969L (no) Ikke-replikerende rekombinant fremstilte retroviruspartikler brukt som antivirale midler og immunogener
ES2177695T3 (es) Uso de derivados funcionales de la molecual de adhesion intercelular icam-1 en terapia antiviral.
EA201000829A1 (ru) Вакцина
Awasthi et al. A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model
ATE179614T1 (de) Herpes simplex virus vp16 impfstoffe
FI970786A0 (fi) 4-/2-amino-6-(syklopropyyliamino)-9H-purin-9-yyli)-2-syklopenteeni-1-metanoli-sukkinaatti viruksia torjuvana aineena
Fomsgaard HIV-1 DNA vaccines
Boffito et al. Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial
Potts et al. Genetic diversity of human immunodeficiency virus type 1 strains in Kinshasa, Zaire
Locher et al. Short Communication Antibody and Cellular Immune Responses in Breakthrough Infection Subjects after HIV Type 1 Glycoprotein 120 Vaccination
Moingeon et al. Therapeutic vaccines against infectious diseases
ES2500265T3 (es) Proteína Tat Oyi mutada para prevenir o tratar SIDA

Legal Events

Date Code Title Description
FA Abandonment or withdrawal